Revealing Lung Cancer Insights
Plasma proteome profiling at scale for biomarker discovery
Lung cancer is the leading cause of cancer-related deaths worldwide, yet studying the disease has remained challenging due to complex etiological factors.
This webinar explores the latest breakthroughs in lung cancer research. Leading experts share insights from one of the largest multiomics observational studies and the novel lung cancer biomarkers discovered through blood plasma proteome analysis using Seer’s cutting-edge Proteograph™ workflow and nanoparticle technology.
We highlight the extensive clinical applications of multiomics in population-scale biomarker discovery studies, shedding new light on its potential to hold the key to improving early-stage lung cancer diagnostics and characterizing complex diseases.
Be among the pioneering researchers with the complete picture of how the initial bioinformatic analyses from the study is now in use.
This webinar is best for:
- Proteomics and multiomics research professionals.
- Scientists focused on lung cancer research and oncology.
- General scientific community.
Things you’ll learn about:
- How researchers detected >8,500 protein groups with intra-study CV’s of <35% in a multi-cancer cohort of ~3,000 subjects.
- Ways peptide and RNA transcript in plasma proteome analysis is advancing early-stage lung cancer diagnostics.
- The accuracy of non-invasive multiomics approaches for lung cancer research, enhancing diagnostic precision and population-wide biomarker discovery studies.
- Transformative techniques to identify novel cancer biomarkers and elevate your oncology research.
- The power of proteomics and the Proteograph workflow in helping transform lung cancer diagnostics and treatment.
Featured Speakers
Bruce Wilcox, Ph.D. Chief Technology Officer, PrognomiQ
Shao-Yung (Eric) Chen, Ph.D. Marketing Application Scientist, Seer
Watch Webinar On-Demand
Fill out the form to watch the webinar.